

PEER-REVIEW REPORT

Name of journal: World Journal of Experimental Medicine

Manuscript NO: 40555

Title: Predictive markers of endocrine response in breast cancer

Reviewer's code: 03105058

Reviewer's country: United States

Science editor: Fang-Fang Ji

Date sent for review: 2018-06-30

Date reviewed: 2018-06-30

Review time: 0 Hour

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input checked="" type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input checked="" type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This is a well written manuscript on a topic with important clinical implications. The results support the conclusions

INITIAL REVIEW OF THE MANUSCRIPT



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https:// www.wjgnet.com

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ No

PEER-REVIEW REPORT

Name of journal: World Journal of Experimental Medicine

Manuscript NO: 40555

Title: Predictive markers of endocrine response in breast cancer

Reviewer's code: 00181208

Reviewer's country: Canada

Science editor: Fang-Fang Ji

Date sent for review: 2018-06-30

Date reviewed: 2018-07-13

Review time: 13 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input checked="" type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input checked="" type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input checked="" type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input checked="" type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input checked="" type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input checked="" type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

This is a useful general outline of the endocrine therapy predictive biomarkers landscape in breast cancer. It may serve as a general reference on the subject and a look-out for upcoming developments. Some specific points: - In the first paragraph of page 4 it should be clarified that the discussion refers to metastatic disease. - In the second

paragraph of page 5 it should be clarified that the described acquired resistance related to ER loss happens following neo-adjuvant treatment. - In the last paragraph of page 5 continuing in the next page a reference to CDK inhibitors as a means of overcoming resistance and putative predictive markers should be mentioned in addition to the other inhibitors of PI3K and mTOR considering that CDK-CyclinD-Rb may be positioned downstream. - In the multigene signature section it should be stressed that the use of these signatures are in adjuvant setting. - The last sentence of the 1st paragraph of page 7 is not very clear. All predictive biomarkers are derived from studying groups of patients and define a statistical probability for the individual patient. In addition, the oncotype dx signature mentioned just below provides a specific distant recurrence probability at 10 years in the individual patient. - Later in the same paragraph it should be mentioned that the recently published intermediate group TAILORx study does not exclude a benefit of chemotherapy for pre-menopausal patients with a high-intermediate score. -In page 8, third paragraph. The sentence implies that prognostic markers (in this case of distant recurrence) are also predictive of response to therapy (in this case chemotherapy) which is not correct. Authors should modify. - In page 10 NET should be explained. - In the table it should be MKI67 and ERBB2 (instead of HER2). Also in the table it could be useful to add columns with the indications of the tests and populations that have validation data. - A brief discussion of alternative ERs (ERbeta, truncated ERs and GPER1) as predictive biomarkers could be of interest.

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA

Telephone: +1-925-223-8242

Fax: +1-925-223-8243

E-mail: bpgoffice@wjgnet.com

<https://www.wjgnet.com>

[Y] No

BPG Search:

[] The same title

[] Duplicate publication

[] Plagiarism

[Y] No

PEER-REVIEW REPORT

Name of journal: World Journal of Experimental Medicine

Manuscript NO: 40555

Title: Predictive markers of endocrine response in breast cancer

Reviewer's code: 03010350

Reviewer's country: Russia

Science editor: Fang-Fang Ji

Date sent for review: 2018-06-30

Date reviewed: 2018-07-15

Review time: 15 Days

SCIENTIFIC QUALITY	LANGUAGE QUALITY	CONCLUSION	PEER-REVIEWER STATEMENTS
<input type="checkbox"/> Grade A: Excellent	<input type="checkbox"/> Grade A: Priority publishing	<input type="checkbox"/> Accept	Peer-Review:
<input type="checkbox"/> Grade B: Very good	<input type="checkbox"/> Grade B: Minor language	(High priority)	<input type="checkbox"/> Anonymous
<input type="checkbox"/> Grade C: Good	polishing	<input type="checkbox"/> Accept	<input type="checkbox"/> Onymous
<input type="checkbox"/> Grade D: Fair	<input type="checkbox"/> Grade C: A great deal of	(General priority)	Peer-reviewer's expertise on the
<input type="checkbox"/> Grade E: Do not	language polishing	<input type="checkbox"/> Minor revision	topic of the manuscript:
publish	<input type="checkbox"/> Grade D: Rejection	<input type="checkbox"/> Major revision	<input type="checkbox"/> Advanced
		<input type="checkbox"/> Rejection	<input type="checkbox"/> General
			<input type="checkbox"/> No expertise
			Conflicts-of-Interest:
			<input type="checkbox"/> Yes
			<input type="checkbox"/> No

SPECIFIC COMMENTS TO AUTHORS

Excellent Editorial paper. As for Core type. Sentence "Ki67 expression at baseline and after 2 weeks (after that?) can provide useful prognostic and predictive information..." It will be more understandable if adjuvant therapy is mentioned before it. The article is excellent, but do you need so many co-authors, if this is not original research work?



**Baishideng
Publishing
Group**

7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
https:// www.wjgnet.com

INITIAL REVIEW OF THE MANUSCRIPT

Google Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No

BPG Search:

- ☐ The same title
- ☐ Duplicate publication
- ☐ Plagiarism
- ☐ [Y] No